By Steve Hanley from CleanTechnica —- Worried that alterations to the Earth’s climate may wipe out all the bees, leading to a steep decline in the availability of fruits and vegetables? Fear not. Researchers at MIT say they have successfully created robot bees that can do the job of real bees just as well and maybe better in some cases. […]

Abu Dhabi Launches International Carbon Measurement, Reporting and Verification Programme The Environment Agency – Abu Dhabi (EAD) has launched an international standard carbon Measurement, Reporting, and Verification (MRV) programme to address carbon emissions and accelerate the emirate’s transition to a low-carbon economy. This move supports Abu Dhabi’s broader decarbonisation goals, including reducing carbon emissions by […]

Emirati investment firm Kazar is investing $2.5 billion to build a hybrid renewable energy station in Egypt’s Zafarana region. The project, a collaboration with the Egyptian government, will deliver a total capacity of 3.1 gigawatts—2 GW from solar energy and 1.1 GW from wind energy—making it a key addition to Egypt’s renewable energy infrastructure. The station will operate […]

by venturebeat — In a development straight out of science fiction, Endiatx, a pioneering medical technology company, is making significant strides in bringing its robotic pill to market. The company’s CEO, Torrey Smith, recently sat down with VentureBeat to share exciting updates on their progress, nearly two years after our initial coverage of the startup’s ambitious vision. Founded in 2019, Endiatx has been steadily working towards realizing the fantastic voyage of miniaturized robots navigating the human body for diagnostic and therapeutic purposes. Their flagship product, the PillBot, is an ingestible robotic capsule equipped with cameras, sensors, and wireless communication capabilities, allowing doctors to examine the gastrointestinal tract with unprecedented precision and control.

In the interview, Smith revealed that Endiatx has raised $7 million in funding to date, with the largest investment of $1.5 million coming from Singapore-based Verge Health Tech Fund. This injection of capital has propelled the company forward, enabling them to refine their technology and conduct clinical trials. Join enterprise leaders in San Francisco from July 9 to 11 for our flagship AI event. Connect with peers, explore the opportunities and challenges of Generative AI, and learn how to integrate AI applications into your industry. Register Now “We’re currently in clinical trials with our pill bot technology,” Smith explained. “We’ll be starting pivotal trials at a leading U.S. medical institution in Q3/Q4.” Though Smith did not name the institution due to confidentiality agreements, he hinted that it is a renowned facility known for its expertise in gastroenterology. The PillBot has come a long way since its inception. The current prototype measures just 13mm by 30mm and boasts impressive capabilities. “It can transmit high-res video at 2.3 megapixels per second, and we have plans to quadruple that video quality soon,” Smith enthused. The CEO himself has played a vital role in testing, having swallowed 43 PillBots to date, including live on stage in front of a stunned audience.

by Michael Nuñez @MichaelFNunez – venturebeat –– As companies race to adopt artificial intelligence systems, conventional wisdom suggests that younger, more tech-savvy employees will take the lead in teaching their managers how to effectively use the powerful new tools. But a new study casts doubt on that assumption when it comes to the rapidly-evolving technology of generative AI.

The research, conducted by academics from Harvard Business School, MIT, Wharton, and other institutions in collaboration with Boston Consulting Group, found that junior employees who experimented with a generative AI system made recommendations for mitigating risks that ran counter to expert advice. The findings suggest that companies cannot rely solely on reverse mentoring to ensure the responsible use of AI. “Our interviews revealed two findings that run counter to the existing literature,” wrote the authors. “First, the tactics that the juniors recommended to mitigate their seniors’ concerns ran counter to those recommended by experts in GenAI technology at the time, and so revealed that the junior professionals might not be the best source of expertise in the effective use of this emerging technology for more senior members.”

Junior consultants struggle with AI risk mitigation in GPT-4 experiment The researchers interviewed 78 junior consultants in mid-2023 who had recently participated in an experiment giving them access to GPT-4, a powerful generative AI system, for a business problem-solving task. The consultants, who lacked technical AI expertise, shared tactics they would recommend to alleviate managers’ concerns about risks. But the study found the junior employees’ risk mitigation tactics were often grounded in “a lack of deep understanding of the emerging technology’s capabilities,” focused on changing human behavior rather than AI system design, and centered on project-level interventions rather than organization or industry-wide solutions.

Navigating the challenges of generative AI adoption in business